奎斯特诊断
DGX
235.00
-4.15
-1.74%
奎斯特诊断
US · DGX
#767 按市值排名
上市于 1996
235.00
-4.15
-1.74%
实时 - 追踪5344个代码 - 心跳于542秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了3家。
- 机构持股总比例下降了0.3个百分点。
机构持股
- 机构持股比例
- 97.27% -0.25pp
- 机构数量
- 1,297 -3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund81.70%
Public Company5.34%
Hedge Fund3.90%
Private Company1.95%
Government Pension Fund1.64%
Sovereign Wealth Fund1.33%
Family Office/Trust0.51%
Insurance Company0.45%
Individual/Insider0.36%
Other2.83%
主要股东 截至 2026-06-30
BlackRock
8.40% · 9.28M 股
Vanguard Capital Management, LLC
7.12% · 7.86M 股
Vanguard Portfolio Management, LLC
5.55% · 6.13M 股
State Street Global Advisors
5.00% · 5.52M 股
T. Rowe Price Group, Inc.
4.92% · 5.43M 股
Boston Partners Global Investors, Inc.
4.30% · 4.74M 股
Geode Capital Management, LLC
2.84% · 3.14M 股
J.P. Morgan Asset Management, Inc.
2.79% · 3.08M 股
EdgePoint Investment Group Inc.
2.04% · 2.25M 股
Dimensional Fund Advisors
1.80% · 1.99M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 35次买入 · 15次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| James Davis | Chairperson & CEO | 0.11% |
| Catherine Doherty | Senior Vice President of Regional Businesses | 0.06% |
| Michael Prevoznik | General Counsel | 0.04% |
| Michael Deppe | Senior VP, Corporate Controller & Chief Accounting Officer | 0.03% |
| Sam Samad | Chief Financial Officer | 0.03% |
| Timothy Main | Independent Director | 0.02% |
| Vicky Gregg | Independent Director | 0.02% |
| Karthik Kuppusamy | Senior Vice President of Clinical Solutions | 0.01% |
| Patrick Plewman | Senior Vice President of Diagnostic Services | 0.01% |
| Mark Delaney | Chief Commercial Officer | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Timothy Wentworth | Director | Other Derivative Acquisition | +135 | -- |
| 2026-08-31 | James Davis | Chairperson & CEO | Automatic Disposition | -10,000 | $242.72 |
| 2026-08-27 | Michael Prevoznik | General Counsel | Other Disposition | -1,000 | -- |
| 2026-08-27 | Michael Prevoznik | General Counsel | Derivative Exercise and Sale | -22,677 | $112.17–244.51 |
| 2026-07-27 | Mark Delaney | Chief Commercial Officer | Automatic Disposition | -1,600 | $235.18 |
| 2026-07-21 | Patrick Plewman | Senior Vice President of Diagnostic Services | Other Acquisition | +46 | $206.81 |
| 2026-07-21 | Timothy Main | Independent Director | Other Acquisition | +21 | $206.81 |
| 2026-07-21 | Robert Carter | Director | Other Acquisition | +11 | $206.80 |
| 2026-07-21 | Vicky Gregg | Independent Director | Other Acquisition | +72 | $206.81 |
| 2026-07-21 | Wright Lassiter | Independent Director | Other Acquisition | +6 | $206.81 |
| 2026-07-21 | Sam Samad | Chief Financial Officer | Other Acquisition | +102 | $206.81 |
| 2026-07-21 | Mark Delaney | Chief Commercial Officer | Other Acquisition | +34 | $206.81 |
| 2026-07-21 | Karthik Kuppusamy | Senior Vice President of Clinical Solutions | Other Acquisition | +37 | $206.81 |
| 2026-06-30 | Timothy Wentworth | Director | Other Derivative Acquisition | +144 | -- |
| 2026-06-03 | Karthik Kuppusamy | Senior Vice President of Clinical Solutions | Derivative Exercise and Sale | -8,147 | $121.81–200.00 |
| 2026-05-31 | James Davis | Chairperson & CEO | Automatic Disposition | -10,000 | $194.14 |
| 2026-05-19 | Timothy Main | Independent Director | Other Acquisition | +1,142 | -- |
| 2026-05-19 | Robert Carter | Director | Other Acquisition | +1,142 | -- |
| 2026-05-19 | Timothy Ring | Lead Independent Director | Other Acquisition | +1,142 | -- |
| 2026-05-19 | Gary Pfeiffer | Independent Director | Other Acquisition | +1,142 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
奎斯特诊断 讨论区 0 条评论